Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP972347priorityCriticalpatent/ECSP972347A/en
Publication of ECSP972347ApublicationCriticalpatent/ECSP972347A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Agonistas de prostaglandinas, procedimientos de uso de tales agonistas de prostaglandinas, composiciones farmacéuticas que contienen tales agonistas de prostaglandinas. Los agonistas de prostaglandinas son útiles para el tratamiento de trastornos óseos, incluyendo osteoporosis.Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists. Prostaglandin agonists are useful for the treatment of bone disorders, including osteoporosis.
ECSP9723471997-12-191997-12-19
PREVENTION OF LOSS AND RESTORATION OF THE BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
ECSP972347A
(en)
ADAMANTAN DERIVATIVES, PROCEDURES FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES
N- (INDOL-2-CARBONYL) beta-ALANYLAMIDES SUBSTITUTED AND DERIVED AS INHIBITORS OF GLUCOGEN PHOSPHORYLASE, USE OF THE SAME AND COMPOSITIONS THAT CONTAIN THEM.
NEW THERAPEUTIC COMBINATIONS (S) -2-BENCILAMINO-METIL) -2,3,8,9-TETRAHIDRO-7H-1,4-DIOXINO [2,3-E] INDOL-8-ONA AND NEUROLETICS FOR THE OPREVENTION TREATMENT OF PSYCHOTIC DISORDERS